Reimagining drug
development as it should be.

From drug discovery to drug engineering.

Creyon Bio is reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible. With powerful, purpose-built data sets to drive efficient creation of machine learning models, we engineer oligonucleotide-based medicines (OBMs) for safe, precise gene-centric therapies with unprecedented speed and predictable efficacy and safety. It’s a groundbreaking modular approach that slashes costs for new medicines whether treating disease impacting one patient or millions.

Our Approach

Delivering gene-centric medicines in time
to make a difference.

With partnerships ranging from industry to patient advocates and policymakers, we are working together to build a faster, more cost-effective path to medicines for those who need them most.

Our Work

We dare to color outside the lines.

Our multidisciplinary team of chemists, biologists, and computational scientists is tackling the drug development challenge from all angles.

Our Team

Build a better world of drug development.

Are you ready to be a Creyoneer? Build a faster, more streamlined, and more equitable process for creating new medicines with us.

Join Us

Keep up with
Creyon news

Latest News

Creyon Bio Publishes New Research Establishing Rigorous Quantification Methods of Off-target Analysis in Oligonucleotide Drug Design

Creyon Bio, Inc, a drug development company focused on transforming nucleic-acid medicine drug discovery to drug engineering, published new research greatly increasing their ability to engineer Oligonucleotide-Based Medicines (OBMs) with minimal off-target effects, which will help us evaluate molecules with a higher standard of precision and live up to the full potential of the “super-modality” of oligonucleotide-based medicines.

Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Creyon Bio, Inc. (“Creyon”), a clinical stage drug development company that engineers Oligonucleotide-Based Medicines (OBMs) with industry-leading efficiency creating novel, best-in-class gene-centric medicines to treat rare and common diseases, today announced encouraging clinical data highlighting the use of its custom designed data set paired with artificial intelligence (AI) to rapidly engineer an investigational antisense oligonucleotide (ASO) therapy.

Creyon Bio and Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases

Creyon Bio, Inc. (“Creyon”), a drug development company that engineers Oligonucleotide-Based Medicines (OBMs) with industry leading efficiency creating novel, best-in-class gene-centric medicines to treat rare and common diseases, and Cajal Neuroscience, (“Cajal”), a biotechnology company integrating disease-focused genetics and human data with state-of-the-art experimental capabilities to discover novel targets and therapeutics for neurodegeneration, today announced a partnership to develop novel OBMs for neurodegenerative diseases.

Creyon Bio to Present at Upcoming May 2024 Medical and Industry Conferences

Creyon Bio, Inc. (“Creyon”), a clinical stage biotechnology company engineering and developing Oligonucleotide-Based Medicines (OBMs) for common and rare diseases, today announced that its executives will present and participate in two upcoming medical and industry conferences in May 2024.

Reimagining drugdevelopment as it should be.